Holen Sie sich die Stockscreener-App
28.35
3.58%
0.98
Handel nachbörslich:
28.35
Schlusskurs vom Vortag:
$27.37
Offen:
$27.59
24-Stunden-Volumen:
1.58M
Relative Volume:
0.64
Marktkapitalisierung:
$4.52B
Einnahmen:
$295.41M
Nettoeinkommen (Verlust:
$-49.64M
KGV:
-86.59
EPS:
-0.3274
Netto-Cashflow:
$-29.54M
1W Leistung:
-3.67%
1M Leistung:
+14.96%
6M Leistung:
+91.42%
1J Leistung:
+99.09%
1-Tages-Spanne:
$27.31
$28.41
1-Wochen-Bereich:
$27.14
$29.80
52-Wochen-Spanne:
$12.00
$29.96
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
28.35 | 4.70B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Options exercised over three months will supply an officer's planned sale at Adaptive Biotechnologies (ADPT). - Stock Titan
Adaptive Biotechnologies slips as recent rally cools despite no clear new negative catalyst - Quiver Quantitative
ADPT Maintained by Guggenheim -- Price Target Raised to $32 - GuruFocus
ETFs Investing in Adaptive Biotechnologies Corp. Stocks - TradingView
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rated "Buy" in New Coverage at The Goldman Sachs Group - MarketBeat
ADPT Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus
Adaptive Biotechnologies Corp (ADPT) Stock Down 3.1% but Still O - GuruFocus
Form 4 Adaptive Biotechnologies Corp For: 28 September By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CPO Francis Lo sells $3.2 million in stock - Investing.com
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure - Yahoo Finance
Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now? - Yahoo Finance
Adaptive Biotechnologies Corp (ADPT) Stock Up 6.0% but GF Value Says Overvalued -- GF Score: 68/100 - GuruFocus
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 4.4%Should You Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at 28.79 USD - Investing.com
Adaptive Biotechnologies stock hits 52-week high at 28.79 USD By Investing.com - Investing.com Australia
NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT) - Yahoo Finance
Adaptive Biotechnologies (ADPT) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing? - Insider Monkey
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $34.00 at BTIG Research - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year HighShould You Buy? - MarketBeat
Bank of America Corp DE Makes New Investment in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Tidal Investments LLC Takes $855,000 Position in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies CPO Francis Lo sells $3.2m in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CPO Francis Lo sells $3.2m in stock - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 115,406 Shares - MarketBeat
Adaptive Biotechnologies (ADPT) HR chief sells over 100,000 shares under preset plan - Stock Titan
Adaptive Biotechnologies Corp (ADPT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Adaptive biotechnologies chief commercial officer sells $32,265 in shares. - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 1,195 Shares - MarketBeat
Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells shares under pre-set trading plan - Stock Titan
ADPT Looks 137.6% Overvalued on GF Value™ - GuruFocus
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ® - Yahoo Finance
Alert incorrectly tagged to Adaptive Biotechnologies withdrawn - marketscreener.com
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Adaptive Biotechnologies (ADPT) officer to sell 142K shares - Stock Titan
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week HighTime to Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at 26.89 USD By Investing.com - Investing.com India
A Look at Adaptive Biotechnologies Corp (ADPT) After 7.7% Gain -- GF Value $11.66 vs Price $26.68 - GuruFocus
Officer at Adaptive Biotechnologies (NASDAQ: ADPT) plans sale of 1,195 shares - Stock Titan
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 6.4%What's Next? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at 26.89 USD - Investing.com
Adaptive Biotechnologies Corp (ADPT) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Legal & General Group Plc Takes $7.62 Million Position in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies (NASDAQ: ADPT) director reports stock gift, still holds 66,100 shares - Stock Titan
Wellington Management Group LLP Has $126.80 Million Stake in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Morgan Stanley’s healthcare conference sets a biotech chat for Sept. 15 - Stock Titan
Adaptive Biotechnologies Corp (ADPT) Peer Comparison – Compare with Others - Value Research
Adaptive Biotechnologies Corp (ADPT) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Director Katey Owen Sells 9,615 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
Adaptive Biotechnologies director Owen sells $249,990 in stock. By Investing.com - Investing.com India
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Adaptive Biotechnologies Corp-Aktie (ADPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LO FRANCIS | Chief People Officer |
Sep 16 '26 |
Option Exercise |
9.57 |
105,560 |
1,010,581 |
336,273 |
| LO FRANCIS | Chief People Officer |
Sep 16 '26 |
Sale |
28.06 |
115,406 |
3,238,004 |
220,867 |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD |
Sep 15 '26 |
Sale |
27.00 |
1,195 |
32,265 |
395,794 |
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):